The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly ...

FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant access barriers for patients.

In two recent studies, this new shot reportedly nearly eliminated new infections in people at substantial risk of HIV.

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The Food and Drug Administration (FDA) has approved the HIV preventing drug, lenacapavir, which only has to be administered twice a year. The injectable drug, sold as Yeztugo, can be taken by those at ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the ...

The 2025 Warren Alpert Foundation Prize has been awarded to three scientists whose discoveries culminated in the development ...

Newly FDA-approved HIV prevention drug, Yeztugo, offers protection for six months—yet the need for a vaccine remains, say ...

The FDA has approved Gilead’s long-anticipated HIV prevention shot, Yeztugo, offering a twice-a-year alternative to daily ...

Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.